ACG Clinical Guideline: Gastroparesis
- PMID: 35926490
- PMCID: PMC9373497
- DOI: 10.14309/ajg.0000000000001874
ACG Clinical Guideline: Gastroparesis
Abstract
Gastroparesis is characterized by symptoms suggesting retention of food in the stomach with objective evidence of delayed gastric emptying in the absence of mechanical obstruction in the gastric outflow. This condition is increasingly encountered in clinical practice. These guidelines summarize perspectives on the risk factors, diagnosis, and management of gastroparesis in adults (including dietary, pharmacological, device, and interventions directed at the pylorus), and they represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation process. When the evidence was not appropriate for Grading of Recommendations, Assessment, Development, and Evaluation, we used expert consensus to develop key concept statements. These guidelines should be considered as preferred but are not the only approaches to these conditions.
Copyright © 2022 by The American College of Gastroenterology.
Conflict of interest statement
Potential conflicts of interest:
MC: Single-center research studies: Allergan, Takeda, and Vanda; Consulting with compensation to his employer: Takeda, Alpha Sigma Wasserman
TA: Investigator: Censa, Clndome, Vanda, Allergan, Neurogastrix; Consultant: Censa, Nuvaira, Takeda, Medtronic; Speaker: Takeda, Medtronic; Reviewer: UpToDate; Writer: Med Study; Editorial:
BK: Clinical trials with Takeda, Vanda, Alpha Sigma Wasserman, GSK; Consulting with Takeda, Cindome, Neurogastrix; Speaking for Medtronic
LN: Investigator: Allergan, Vanda; Consultant: Abbvie, Ironwood, Alnylam, Eli Lilly, Gemelli, Neurogastrx, Pendulum, Phathom, RosVivo, Salix, Takeda. Scientific Advisory Board: Gemelli, RosVivo
VMV: Nothing to disclose
JP: Nothing to disclose
KG: Nothing to disclose
RY: Consultant through Institutional Agreement: Medtronic, Ironwood Pharmaceuticals, Diversatek, StatLinkMD; Research support: Ironwood Pharmaceuticals; Advisory Board: Phathom Pharmaceuticals; RJS Mediagnostix
Figures
References
-
- Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592–1622. - PubMed
-
- Nishiwaki S, Kurobe T, Baba A, et al. Prognostic outcomes after direct percutaneous endoscopic jejunostomy in elderly patients: comparison with percutaneous endoscopic gastrostomy. Gastrointest Endosc 2021;94:48–56. - PubMed
-
- Tan Y-W, Yan Ting Chua A, Ng Yin K, et al. Optimal management of gastrojejunal tube in the ENFit era - Interventions that changed practice. J Pediatr Surg 2021; 6:1430–1435. - PubMed
-
- Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416–23 - PubMed